$724 Million is the total value of Avidity Partners Management LP's 52 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RLMD | Exit | RELMADA THERAPEUTICS INC | $0 | – | -10,000 | -100.0% | -0.25% | – |
| ARAV | Exit | ARAVIVE INC | $0 | – | -30,000 | -100.0% | -0.26% | – |
| RCKT | Exit | ROCKET PHARMACEUTICALS INC | $0 | – | -30,000 | -100.0% | -0.43% | – |
| MDGL | Exit | MADRIGAL PHARMACEUTICALS INC | $0 | – | -15,000 | -100.0% | -0.86% | – |
| NLTX | Exit | NEOLEUKIN THERAPEUTICS INC | $0 | – | -210,000 | -100.0% | -1.63% | – |
| EXAS | Exit | EXACT SCIENCES CORP | $0 | – | -31,000 | -100.0% | -1.81% | – |
| DXCM | Exit | DEXCOM INC | $0 | – | -19,000 | -100.0% | -2.62% | – |
| ABEO | Exit | ABEONA THERAPEUTICS INC | $0 | – | -1,325,000 | -100.0% | -2.73% | – |
| NXTC | Exit | NEXTCURE INC | $0 | – | -93,000 | -100.0% | -3.30% | – |
| AXNX | Exit | AXONICS MODULATION TECH INC | $0 | – | -208,000 | -100.0% | -3.63% | – |
| EW | Exit | EDWARDS LIFESCIENCES CORP | $0 | – | -27,000 | -100.0% | -3.97% | – |
| ZBH | Exit | ZIMMER BIOMET HLDGS INC | $0 | – | -54,500 | -100.0% | -5.14% | – |
| HCA | Exit | HCA HEALTHCARE INC | $0 | – | -62,700 | -100.0% | -5.84% | – |
| BAX | Exit | BAXTER INTL INC | $0 | – | -165,000 | -100.0% | -8.69% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC | 15 | Q3 2023 | 4.6% |
| ARVINAS INC | 14 | Q3 2023 | 4.9% |
| ZENTALIS PHARMACEUTICALS INC | 14 | Q3 2023 | 4.8% |
| SYNDAX PHARMACEUTICALS INC | 14 | Q3 2023 | 3.2% |
| IDEAYA BIOSCIENCES INC | 13 | Q3 2023 | 2.5% |
| NATERA INC | 13 | Q3 2023 | 1.9% |
| ALPINE IMMUNE SCIENCES INC | 13 | Q3 2023 | 0.5% |
| ABBVIE INC | 12 | Q2 2023 | 9.7% |
| HORIZON THERAPEUTICS PUB LTD | 12 | Q3 2022 | 3.4% |
| AVANTOR INC | 11 | Q1 2023 | 6.0% |
View Avidity Partners Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Adicet Bio, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| ALPINE IMMUNE SCIENCES, INC. | February 14, 2023 | 1,888,887 | 4.0% |
| ESSA Pharma Inc. | February 14, 2023 | 1,855,400 | 4.2% |
| Gritstone bio, Inc. | February 14, 2023 | 2,859,971 | 3.3% |
| IVERIC bio, Inc. | February 14, 2023 | 838,407 | 0.6% |
| ONCOSEC MEDICAL IncSold out | February 14, 2023 | 0 | 0.0% |
| PhaseBio Pharmaceuticals Inc | February 14, 2023 | 2,040,000 | 4.1% |
| Phathom Pharmaceuticals, Inc. | February 14, 2023 | 1,900,000 | 4.6% |
| Viridian Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Anika Therapeutics, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
View Avidity Partners Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-09 |
| SC 13G | 2024-03-27 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
View Avidity Partners Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.